Article Abstract

Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts

Authors: Kristopher A. Lyon, Jason H. Huang

Abstract

Glioblastoma (GBM) is the most aggressive and common primary brain tumor in adults, recurring in an average of 6.9 months after initial diagnosis even with aggressive treatment (1,2). After initial diagnosis, most patients survive an average of 14 months (3).